Rilzabrutinib ITP denied for missing prior authorization by Cigna?

Cigna's specific coverage criteria for rilzabrutinib itp are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Requires Prior Authorization for Rilzabrutinib in ITP

Prior authorization (PA) is Cigna's gate-keeping step before agreeing to cover a drug. For rilzabrutinib in immune thrombocytopenia, PA is required because the drug is either specialty-tier, high-cost, or subject to utilization-management criteria. A PA denial — or a lapse where PA was never obtained — is not a clinical rejection; it is an administrative finding that the required process was not completed or that the submitted information did not satisfy Cigna's coverage criteria.

## Why This Denial Is Appealable

PA denials are routinely overturned when the right documentation is provided. The insurer cannot simply say requirements were unmet — it must identify which requirement and give you a chance to address it. Under federal law: - ACA §2719 / ERISA §503 guarantee an internal appeal with a written explanation of the specific criteria not satisfied. - External review is available after internal appeal exhaustion; the window is generally up to approximately four months from denial notice — confirm the exact deadline on your Explanation of Benefits. - Expedited review is available when a standard timeline would seriously jeopardize health (for example, active significant bleeding or rapidly declining platelet counts).

## Your Appeal Process and Timeline

1. Call Cigna immediately and request the full PA criteria for rilzabrutinib in ITP — specifically the clinical coverage policy number and the checklist of requirements. 2. Have your prescriber re-examine the PA submission against that checklist; missing items are often the sole reason for denial. 3. File the formal internal appeal with a complete documentation package within the timeframe shown on your denial letter. 4. If denied again, request external review without delay.

## Documentation to Gather

• Diagnosis confirmation: laboratory results and clinical records establishing ITP diagnosis and platelet history.
• Prior-treatment documentation: names, dates, and outcomes for all ITP therapies tried before rilzabrutinib, demonstrating the step-therapy or treatment-history criteria are met.
• Clinical severity evidence: chart notes documenting bleeding events, symptom burden, and functional impact.
• Prescriber medical-necessity letter: detailed clinical rationale referencing Cigna's specific PA criteria and the applicable ASH guideline.
• PA submission record: the original request and any prior correspondence, to identify what was missing.

## Criteria-Mapping Structure

Obtain Cigna's published prior-authorization criteria and the FDA-approved prescribing information for rilzabrutinib. List each PA requirement in a table with a dedicated column for the chart evidence or documentation that satisfies it. Submit this table with your appeal so the reviewer can verify each element without searching. Gaps are harder to deny when they are explicitly addressed.